Matthew Wilson
Last active: 3/24/2020

  1. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ (2010) Hum Gene Ther 21(4): 427-37
    › Primary publication · 19905893 (PubMed) · PMC2938363 (PubMed Central)
  2. Multiplexed transposon-mediated stable gene transfer in human cells. Kahlig KM, Saridey SK, Kaja A, Daniels MA, George AL, Wilson MH (2010) Proc Natl Acad Sci U S A 107(4): 1343-8
    › Primary publication · 20080581 (PubMed) · PMC2824351 (PubMed Central)
  3. Designing and testing chimeric zinc finger transposases. Wilson MH, George AL (2010) Methods Mol Biol : 353-63
    › Primary publication · 20680846 (PubMed)
  4. PiggyBac transposon-based inducible gene expression in vivo after somatic cell gene transfer. Saridey SK, Liu L, Doherty JE, Kaja A, Galvan DL, Fletcher BS, Wilson MH (2009) Mol Ther 17(12): 2115-20
    › Primary publication · 19809403 (PubMed) · PMC2814386 (PubMed Central)
  5. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR, June CH, Rooney CM, Wilson MH (2009) J Immunother 32(8): 826-36
    › Primary publication · 19752751 (PubMed) · PMC2796278 (PubMed Central)
  6. Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. Galvan DL, Nakazawa Y, Kaja A, Kettlun C, Cooper LJ, Rooney CM, Wilson MH (2009) J Immunother 32(8): 837-44
    › Primary publication · 19752750 (PubMed) · PMC2796288 (PubMed Central)
  7. PiggyBac transposon-mediated gene transfer in human cells. Wilson MH, Coates CJ, George AL (2007) Mol Ther 15(1): 139-45
    › Primary publication · 17164785 (PubMed)
  8. Functional zinc finger/sleeping beauty transposase chimeras exhibit attenuated overproduction inhibition. Wilson MH, Kaminski JM, George AL (2005) FEBS Lett 579(27): 6205-9
    › Primary publication · 16243318 (PubMed)
  9. Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists. Tan CM, Wilson MH, MacMillan LB, Kobilka BK, Limbird LE (2002) Proc Natl Acad Sci U S A 99(19): 12471-6
    › Primary publication · 12205290 (PubMed) · PMC129469 (PubMed Central)
  10. The role of a conserved inter-transmembrane domain interface in regulating alpha(2a)-adrenergic receptor conformational stability and cell-surface turnover. Wilson MH, Highfield HA, Limbird LE (2001) Mol Pharmacol 59(4): 929-38
    › Primary publication · 11259639 (PubMed)